Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• Underwent surgical procedure for cancer diagnosis or treatment
• Experiencing persistent pain for at least 1 month
• * Pain must have neuropathic features (e.g., burning, shooting, stabbing, tingling, or pain from light touch)
• * Anatomically related to the surgical site and compatible with nerve injury
• * Pain rating of at least 4 out of 10 on the pain scale
• No pain of multiple etiologies at the proposed treatment site (e.g., pain of neuropathic and muscular or skeletal origin)
• Painful area must be no larger than can be covered by 3 lidocaine patches\* NOTE: \*Each patch size is 5.5 x 4 inches
• No skin disease, breakdown, infection, or extreme thinning at the site of pain
• No skin or soft tissue malignancy in the painful area
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Not specified
• Life expectancy
• At least 6 months
• Hematopoietic
• Not specified
• Hepatic
• AST ≤ 2 times upper limit of normal
• Renal
• Not specified
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to understand and complete questionnaires
• No recent history of or concurrent drug or alcohol abuse
• No mental or psychiatric condition that would preclude giving informed consent
• No history of allergic reaction or intolerance to lidocaine or other amide local anesthetics (e.g., bupivacaine)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No prior neurotoxic chemotherapy\* with pain in the same area as postsurgical neuropathic pain, except for pain that was present before neurotoxic chemotherapy administration
• No concurrent neurotoxic chemotherapy\* NOTE: \*Including taxanes (e.g., paclitaxel or docetaxel), platinum-based compounds (e.g., cisplatin or carboplatin), or vinca alkaloids (e.g., vincristine or vinblastine)
• Endocrine therapy
• More than 7 days since prior topical corticosteroids to the painful area
• No new corticosteroids may be initiated during study participation
• Radiotherapy
• No concurrent radiotherapy to the painful area
• Surgery
• See Disease Characteristics
• Other
• More than 7 days since other prior topical medications to the painful area (including capsaicin)
• No change in current analgesic regimen within the past 10 days
• No new analgesic or adjuvant drugs (e.g., antidepressants, anticonvulsants, or anxiolytics) may be initiated during study participation
• * Concurrent stable doses of nonopioid, opioid, and adjuvant analgesic drugs are allowed (including antidepressants or anticonvulsants)
• No concurrent class I antiarrhythmic drugs (e.g., tocainide and mexiletine)
• Concurrent skin lubricants and sunscreen are allowed provided they are not heavily applied